Fortacin Prilocaine Lidocaine Spray
What Is TEMPE Spray?
Clinical Trials Results
Side-Effects
Can I Buy Fortacin Spray?
Resources


Clinical Trials Results

Latest clinical data confirms the effectiveness and positive safety profile of Tempe Spray for men with Premature Ejaculation

New data results presented to the 2010 American Urological Association Annual Meeting in San Francisco demonstrated that 536 men suffering Premature Ejaculation and treated with TEMPE Spray 5 minutes before intercourse were able to maintain an erection 5.5 times longer than men who used the placebo spray.

Men from 70 centers in the USA, Canada and Europe with Premature Ejaculation were evaluated with TEMPE spray over a three-month period with 23,000 exposures recorded. Only 5 percent of the men’s sexual partners reported burning sensation in the vulvovaginal area, while 3.1 percent of men reported loss of erection.

 

TEMPE Spray Phase III


FDA USA Phase III clinical results confirm:

Tempe Spray has met all co-primary endpoints:

  • The intra-vaginal ejaculation latency time (IELT) was increased at least six-fold with Tempe Spray when compared to baseline.
  • There was a 5 point difference between Tempe Spray and placebo in the Index of Premature Ejaculation (IPE) domains for ejaculatory control and sexual satisfaction, where a 2 point difference is considered clinically significant.
  • IPE domain for Distress was a 2.5-point difference between Tempe Spray and placebo, where a 2 point difference is considered clinically significant.
  • And partner satisfaction, as a secondary endpoint, was also found considerably greater with Tempe Spray than placebo.

Tempe Spray was well tolerated and only a very low incidence of mild penile numbing (<3%) was observed.

Tempe Spray would be the first prescription treatment in the United States for premature ejaculation, upon FDA approval.


Similar positive results confirmed in European Phase III study:

European Phase III study of Tempe Spray for the treatment of premature ejaculation in Europe is completed and met all the goals of its European Phase III trial.

European Phase III clinical results confirm:

  • Both Patient and Partner Satisfaction Increased Significantly
  • 86 percent of Patients Rated the Treatment as Positive
  • Well Tolerated and Devoid of Systemic Side Effects

The number of patients in the Tempe Spray group who rated the quality of their orgasm as good or very good increased from 20 percent at baseline to 62 percent after treatment. In comparison, the number of placebo-treated patients with this rating decreased from 21 percent to 19 percent.

The Principal Investigator in the study, Prof Wallace Dinsmore, Royal Victoria Hospital, Belfast commented:

  • “These results are as impressive as those observed with the phosphodiesterase inhibitors (PDEi) in erectile dysfunction at an equivalent stage of development. The positive impact of Tempe Spray on both patients and their partners could save many relationships”.

Once the results from the US Phase III study become available in the first half of 2009, the data from the two studies will be combined for submission for regulatory approval in the USA and Europe.


Final analyses confirmed that Tempe Spray produced a highly clinically and statistically significant increase from baseline in all three co-primary study endpoints. The intravaginal ejaculation latency time (IELT) geometric mean for Tempe Spray was 4 minutes compared to 1 (one) minute in placebo (p<0.0001).

There was a 7 point difference between Tempe Spray and placebo in the IPE domain for Ejaculatory Control (p<0.0001) and a 6 point difference between Tempe Spray and placebo in the IPE domain for Sexual Satisfaction (p<0.0001), where a 2 point difference in a 16 point range is considered clinically significant.

There were no serious adverse events and only 2.6% of patients reported treatment-related adverse events in the Tempe Spray group compared with 1% in the placebo. Tempe Spray was well tolerated and there were no systemic adverse events.

Of these adverse events, only one patient who received Tempe Spray (0.5%) reported temporary numbness of the penis, which was described as mild.

The European study was conducted with 300 randomized patients across 32 investigational centers in four countries across Europe. Of these, 268 patients have now been entered into the optional nine-month open-label study.

TEMPE Spray Phase III recruitment programme in the USA is now completed for the treatment of premature ejaculation, marking the final stage of the clinical development for this product.

Plethora Solutions, which funded the study, intends to submit the drug for regulatory approval when it has completed its U.S. trial, expected in the first half of 2009.


Clinical data results confirm:

  • The product is applied locally when needed (often referred to as “on demand” therapy)
  • Rapid onset of action is within minutes (<5) and that the benefit will last for at least 2 hours
  • Is well-tolerated: minimal partner transfer eliminating the need to use a condom for protection from the product and the potential for the dose to be self-titrated or adjusted under physician direction
  • No unexpected adverse events; negligible systemic toxicity


Phase II

Researchers from the UK and Netherlands studied 54 men with premature ejaculation, recruited from six hospitals and medical centres across the UK – Sheffield, Manchester, Durham, Plymouth, Belfast and London – and one in The Hague. The men were aged from 18 to 75, with an average age of 39.

Before using the spray, the 54 heterosexual men in the study ejaculated, on average, one minute after vaginal penetration.

The men or their partners used a stopwatch to measure the time from vaginal penetration to ejaculation.

A phase II study data show on average, men who got the spray lasted 2.4 times longer than those who got the placebo.

 
Men using TEMPE Spray
Men using placebo
Lasting time increased
to 2 minutes or more
55%
35%
Lasting time increased
to 3 minutes or more
40%
13%
Lasting time increased
to 4 minutes or more
20%
13%

20 TEMPE users and 23 placebo users completed the study and 83 per cent of all users found the spray easy to use.

Both groups were advised not to use the spray more than once in any 24-hour period to avoid possible bias resulting from too frequent ejaculation.

No adverse effects were found during patient safety checks, which included vital signs, physical findings, electrocardiograms, haematology, biochemistry and urine analysis.

Three men reported numbness in their penis, one said he was unable to get an erection and one partner reported a mild burning sensation each time the spray was used, but continued with the treatment.

 


"At the moment, only a small number of men with premature ejaculation seek or receive treatment from a healthcare professional and the lack of effective pharmacological treatment is a contributory factor" concludes co-author Dr Michael Wyllie from Plethora Solutions Ltd, which manufactures the TEMPE spray.


 


Fortacin Spray Frequently Asked Questions


 

What Is TEMPE Spray?
Clinical Trials Results
Side-Effects
Can I Buy Fortacin Spray?
Resources


Lidocaine Prilocaine Plethora Fortacin Spray News Main Page


 

 

The contents of this site are for informational purposes only and should not be construed as medical advice or substitute for professional care.
You should always consult a doctor with any questions you may have regarding a medical condition.

For comments: info@ejaculationspray.com